Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study

Fedricker D Barber

doi:10.4103/apjon.apjon_49_20

Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study

Asia Pac J Oncol Nurs. 2020 Nov 21;8(1):103-105. doi: 10.4103/apjon.apjon_49_20. eCollection 2021 Jan-Feb.

Author

Fedricker D Barber¹

Affiliation

¹ Department of Investigational Cancer Therapeutics (A Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a rare potential immune-related adverse event (irAE) of checkpoint inhibitors. PRES is a disorder that has a variety of clinical and radiological features, which makes it a challenge for advanced practice registered nurses to diagnose. IrAEs such as PRES require prompt recognition and intervention to optimize clinical outcomes.

Keywords: Checkpoint inhibitors; Phase I clinical trial; posterior reversible encephalopathy syndrome.

Publication types

Case Reports